Stratagene Launches ArrayAssist(R) CopyNumber; Only Guided Workflow Available to Biologists for Copy Number Analysis; Entire Ar

Stratagene Corporation (NASDAQ:STGN), a leading
developer, manufacturer and marketer of specialized life science
research and diagnostic products, today announced the launch of its
ArrayAssist(R) Copy Number Software. This powerful yet extremely
intuitive software is the only guided workflow presently available for
copy number analysis, enabling researchers to easily manipulate and
analyze the massive data sets generated by leading chromosomal copy
number microarrays.
   The ArrayAssist Copy Number software is Stratagene's most recent
application on the ArrayAssist platform, which includes ArrayAssist(R)
Expression and ArrayAssist(R) Exon, the latest versions of which were
introduced in January 2006. All ArrayAssist applications have earned
GeneChip-compatible(TM) status with the Affymetrix platform. They will
soon be provided as universal binaries, able to run natively on the
latest Intel-based Macintosh(R) computers, and are compatible with
Mac(R) OS X, Windows(R), and Linux(R).
   "Our ArrayAssist platform is deliberately designed to make
sophisticated, high-density array analysis accessible to the life
scientist," said David Edwards, Director, Software Solutions at
Stratagene. "The most current microarrays for exon, copy number and
expression analysis generate data sets that break most traditional
analytical tools. With a full spectrum of advanced analytical features
and dynamic interactive visualizations, Stratagene's intuitive,
easy-to-use ArrayAssist platform helps biologists and biostatisticians
conduct independent advanced microarray data analysis."
   ArrayAssist Copy Number supports the identification of biomarkers
for cancer, degenerative disease and developmental disorders by
highlighting chromosomal amplifications and deletions. Biologists can
compare their experimental data in ArrayAssist CopyNumber with a
reference genome using ArrayAssist's integrated genome browser, a
feature of all ArrayAssist applications, and map biological pathways
for a comprehensive understanding of the relevant relationships in
their system with the integration of Stratagene's PathwayArchitect(TM)
platform.
   Stratagene will be demonstrating ArrayAssist Copy Number in Booth
#6 at the Cambridge HealthTech Institute's Microarray Data Analysis
and Interpretation conference, being held at the Ritz-Carlton in
Washington D.C., from August 23 to 25, 2006.
   Stratagene's ArrayAssist and PathwayArchitect products suites are
powered by the award-winning avadis(TM) technology and are
co-developed with Strand Life Sciences.

   About ArrayAssist

   The ArrayAssist product suite provides easy to use,
biology-focused workflows designed to process a wide variety of gene
expression arrays, from raw .CEL data through primary expression and
quality analysis to advanced gene-level and exon-level analysis. It
has a comprehensive suite of tools to examine both transcriptional and
splicing regulation using the Affymetrix GeneChip arrays as well as
advanced analytical features such as multi-way ANOVA, non-parametric
statistical tests, classifiers for machine learning-based prediction
and sophisticated, interactive visualization options. The ArrayAssist
Expression, ArrayAssist Exon, and ArrayAssist Copy Number products are
fully integrated with Stratagene's PathwayArchitect systems biology
pathway analysis software.

   About Stratagene Corporation

   Stratagene is a developer, manufacturer and marketer of
specialized life science research and diagnostic products. The
Company's life science research unit supports advances in science by
inventing, manufacturing and distributing products that simplify,
accelerate and improve research. These products are used throughout
the academic, industrial and government research sectors in fields
spanning molecular biology, genomics, proteomics, drug discovery and
toxicology. The Company's diagnostic unit develops and manufactures
products for urinalysis, and high quality automated instrument and
reagent systems that use blood samples to test for more than 1,000
different allergies and autoimmune disorders. In addition, by
combining its expertise in diagnostics and molecular biology, as well
as its experience with FDA regulatory procedures, the Company is
pursuing opportunities to expand its product portfolio to include
molecular diagnostic kits and instrumentation. More information is
available at http://www.stratagene.com.

   Safe Harbor Statement

   Certain statements in this news release that are not historical
fact constitute "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Stockholders and
other readers are cautioned not to place undue reliance on these
forward-looking statements. Stratagene generally identifies
forward-looking statements by using words like "believe," "intend,"
"target," "expect," "estimate," "may," "should," "plan," "project,"
"contemplate," "anticipate," "predict" or similar expressions. You can
also identify forward-looking statements by discussions of
strategies, plans or intentions. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors,
which may cause the actual results of Stratagene to be materially
different from historical results or from any results expressed or
implied by such forward-looking statements. Among the important
factors that could cause actual results to differ materially from
those contained in or implied by the forward-looking statements are
risks associated with the company's inability to sufficiently
anticipate market needs and develop products and product enhancements
that achieve market acceptance, including molecular diagnostic testing
kits and related products, the company's ability to compete
effectively in the diagnostics and life sciences research markets,
variability of the company's quarterly revenues and operating results,
the failure of the company to retain key employees, the company's
ability to obtain additional debt or equity financing, the possibility
of declining sales due in part to a reduction in research and
development budgets or government funding, the company's ongoing
ability to protect its own intellectual property rights and to avoid
violating the intellectual property rights of third parties, extended
manufacturing difficulties and currency fluctuations. For more
information about these and other factors that could cause actual
results to differ materially from those contained in or implied by the
forward-looking statements please see "Factors that May Affect Future
Results" included in Stratagene's Annual Report on Form 10-K for the
year ended December 31, 2004 and in other reports filed by Stratagene
from time to time with the Securities and Exchange Commission,
including Quarterly Reports on Form 10-Q.

   NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered
trademarks owned or used by Affymetrix Inc.